Navigation Links
Vermillion Reports First Quarter 2013 Results

AUSTIN, Texas, May 15, 2013 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a molecular diagnostics company focused on gynecologic cancers and women's health, reported on its financial results for the first quarter ended March 31, 2013.

Q1 2013 Financial Results
Total revenue in the first quarter of 2013 was $328,000, compared to $312,000 in the same year-ago quarter. First quarter 2013 revenue was comprised of $214,000 in OVA1 product sales and $114,000 in license revenue, as compared to $198,000 of OVA1 product sales and $114,000 in license revenue in the year-ago quarter.

First quarter of 2013 product revenue was derived from 4,274 OVA1 tests performed at the fixed $50 per test as reported by the company's OVA1 marketing partner, Quest Diagnostics. This was an 8% increase from 3,952 OVA1 tests performed at the fixed $50 per test in the year-ago quarter.

The OVA1 product revenue in both periods does not include the additional royalty component of revenue based on 33% of Quest Diagnostics gross margin. Vermillion recognizes this portion of revenue when it is reported by Quest Diagnostics in an annual 'true-up' after the end of the calendar year.  The true-up is based on reimbursed and unreimbursed tests for which Quest Diagnostics considers the payment status as final. For the full year of 2012, the true-up provided $816,000 in revenue to Vermillion or an additional $60 per test.

Total operating expenses in the first quarter of 2013 were $2.9 million as compared to $2.4 million in the same year-ago quarter. The increase is primarily due to one-time items, including costs related to the delayed 2012 annual shareholder meeting held in March 2013, a proxy contest and CEO transition, partially offset by lower sales and marketing costs. Net loss for the first quarter was $2.6 million or $(0.17) per share, as compared to $1.8 million or $(0.12) per share in the same year-ago quarter.

As of March 31, 2013, cash and equivalents totaled $5.8 million. Following the private placement completed on May 13, 2013, Vermillion had approximately $16.6 million in cash and equivalents.  The company plans to use the cash on hand and the expected proceeds from exercise of the warrants to accelerate its research, clinical and commercialization programs.  As a result, guidance for 2013 cash-based operating expenditures is being increased to a range of $12 million to $13 million versus the previous guidance of $9.5 million to $10 million.

2013-2015 Objectives
The recently completed investment transaction was structured to provide funding for the company's 2013-2015 strategic plan.
"This investment in Vermillion positions us to improve the quality of care for women with ovarian cancer," said Thomas McLain , Vermillion's president and CEO. "It provides both strategic and financial resources to build on our early success with OVA1 as the first FDA-cleared multi-biomarker blood test to aid in the diagnosis and treatment of ovarian cancer."

"Our experience in growing the OVA1 market with Quest Diagnostics has defined the key factors for building market awareness and expanding its use," continued McLain. "In 2013 and 2014 we will focus on positioning the patient outcome and cost advantages of the on-label usage of OVA1 versus off-label usage of CA-125 for the pre-surgical triage of suspicious ovarian masses." 

Proceeds from the transaction will support the generation of additional clinical and economic data aligned with the company's efforts to secure treatment guideline support and expanded insurance coverage. These studies will also be essential to building understanding of the benefits of integrating OVA1 with current clinical practice and showing how OVA1 can greatly reduce the percentage of women who receive substandard care.  

The funding will also support two important strategic initiatives:

  • The company will migrate OVA1 to a state-of-the-art clinical testing platform commonly available around the world.  This will expand the market for the test to more laboratories and hospitals and enable licensing OVA1 in non-U.S. markets. It will require the successful execution of validation and clinical studies to support submission of a 510-K and FDA clearance. The company targets launch on this new platform by the end of 2014.
  • The company will also use the funding to accelerate the development of a next generation ovarian cancer diagnostic. This test will utilize a combination of current and novel biomarkers in a new algorithm to increase specificity and positive predictive value, while significantly reducing false positives. The company expects to announce proof of concept results during the second quarter and targets the launch of a next generation test in 2015.
  • Conference Call and Webcast
    Vermillion will hold a conference call to discuss its first quarter results later today, Wednesday, May 15, 2013 at 4:30 p.m. Eastern time. Vermillion's President and CEO Thomas McLain will host the call, followed by a question and answer period.

    Date: Wednesday, May 15, 2013
    Time: 4:30 p.m. Eastern time
    Dial-In number: 1-800-709-0218
    International: 1-212-231-2915
    Conference ID: 21656230

    The conference call will be webcast live and available for replay via the investor section of the company's website at

    Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Liolios Group at 1-949-574-3860.

    A replay of the call will be available approximately two hours after the call through May 29, 2013.

    Toll-free replay number: 1-800-633-8284
    International replay number: 1-402-977-9140
    Replay ID: 21656230

    About Vermillion
    Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, vascular medicine and women's health.

    The company's lead diagnostic, OVA1®, is a blood test for pre-surgical assessment of tumors for malignancy, using a unique multi-biomarker approach. In a published clinical trial, OVA1 achieved 99% sensitivity in detecting epithelial ovarian cancers (EOC). This included 96% sensitivity for stage I EOC, the earliest and curable EOC stage, compared with 57% for the conventional biomarker CA125. In addition, OVA1 found 82% of malignancies missed by non-specialist pre-surgical assessment, and it increased detection of malignancy over ACOG guidelines from 77% to 94%. As the first protein-based, In Vitro Diagnostic Multivariate Index Assay (IVDMIA) cleared by the FDA, OVA1 also represents a new class of software-based diagnostics. Additional information about these published clinical trials is available on Vermillion's website at

    Forward-Looking Statement
    Certain matters discussed in this press release contain forward-looking statements that involve significant risks and uncertainties, including statements regarding Vermillion's plans, objectives, expectations and intentions. These forward-looking statements are based on Vermillion's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Vermillion notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty as to Vermillion's ability to protect and promote its proprietary technology; (2) Vermillion's lack of a lengthy track record successfully developing and commercializing diagnostic products; (3) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its future diagnostic products; (4) uncertainty of the size of market for its existing diagnostic tests or future diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payers such as private insurance companies and government insurance plans; (5) uncertainty that Vermillion has sufficient cash resources to fully commercialize its tests and continue as a going concern; (6) uncertainty whether the trading in Vermillion's stock will become significantly less liquid; and (7) other factors that might be described from time to time in Vermillion's filings with the Securities and Exchange Commission. All information in this press release is as of the date of this report, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Vermillion's expectations or any change in events, conditions or circumstances on which any such statement is based, unless required by law.

    This release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent reports on Form 10-K and Form 10-Q. Copies are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at

    Investor Relations Contact:
    Liolios Group, Inc.
    Ron Both
    Tel 1-949-574-3860 Vermillion, Inc. Consolidated Balance Sheets(Amounts in Thousands, Except Share and Par Value Amounts)(Unaudited)March 31,December 31,20132012AssetsCurrent assets:Cash and cash equivalents

    8,007Accounts receivable

    184137Prepaid expenses and other current assets

    359348Total current assets

    6,3778,492Property and equipment, net

    121142Other assets

    8-Total assets

    8,634Liabilities and Stockholders' EquityCurrent liabilities:Accounts payable

    525Accrued liabilities

    9641,074Short-term debt

    1,1061,106Deferred revenue

    709492Total current liabilities

    3,5733,197Deferred revenue

    656770Total liabilities

    4,2293,967Commitments and contingenciesStockholders' equity:Preferred stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding at March 31, 2013  and December 31, 2012, respectively

    --Common stock, $0.001 par value, 150,000,000 shares authorized; 15,213,246 and 15,200,079 shares issued and outstanding at March 31, 2013 and December 31, 2012, respectively

    1515Additional paid-in capital

    328,278328,097Accumulated deficit

    (326,016)(323,445)Total stockholders' equity

    2,2774,667Total liabilities and stockholders' equity

    8,634Vermillion, Inc. Consolidated Statements of Operations and Comprehensive Loss(Amounts in Thousands, Except Share and Per Share Amounts)(Unaudited)Three Months Ended March 31, 20132012Revenue:Product


    114114Total revenue

    328312Cost of revenue:Product

    3738Total cost of revenue

    3738Gross profit

    291274Operating expenses:Research and development(1)

    484452Sales and marketing(2)

    1,0721,518General and administrative(3)

    1,337468Total operating expenses

    2,8932,438Loss from operations

    (2,602)(2,164)Interest income

    28Interest expense

    -(65)Gain on litigation settlement, net

    -379Reorganization items

    -88Other income (expense), net

    29(22)Loss before income taxes

    (2,571)(1,776)Income tax benefit (expense)

    --Net loss

    (1,776)Net loss per share - basic and diluted

    (0.12)Weighted average common shares used to compute basic and diluted net loss per common share

    15,201,61614,903,455Net loss

    (2,571)(1,776)Foreign currency translation adjustment

    -(3)Comprehensive loss

    (1,779)Non-cash stock-based compensation expense included in operating expenses:(1)  Research and development

    34(2)  Sales and marketing

    5436(3)  General and administrative


    SOURCE Vermillion, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Vermillion Sharpens Focus and Streamlines Operations in 2012
    2. Vermillion Reports Fourth Quarter and Full Year 2011 Results
    3. Vermillion Reports First Quarter 2012 Results
    4. Concerned Stockholders Launch Save Vermillion! Website:
    5. Vermillion to Participate in Lazard Capital Markets 5th Annual Medical Technology Snowbird Conference on February 27, 2013
    6. Vermillion to Report Results for Fourth Quarter and Full Year 2012 on Wednesday, February 20, 2013
    7. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    8. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    9. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    10. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    11. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    Post Your Comments:
    (Date:11/26/2015)... MUMBAI , November 26, 2015 ... --> Accutest Research ... accredited Contract Research Organization (CRO), has ... Chase Cancer Center - Temple Health ... ,     (Photo: ) ...
    (Date:11/25/2015)... 25, 2015 2 nouvelles études permettent ... les différences entre les souches bactériennes retrouvées dans la ... des êtres humains . Ces recherches  ouvrent une nouvelle ... prise en charge efficace de l,un des problèmes ... chats .    --> 2 nouvelles études ...
    (Date:11/25/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: AEZ) ... remain fundamentally strong and highlights the following developments: ... DSMB recommendation to continue the ZoptEC Phase 3 ... final interim efficacy and safety data , ... with heavily pretreated castration- and Taxane-resistant prostate cancer ...
    (Date:11/25/2015)... San Francisco, CA (PRWEB) , ... November 25, ... ... leading microbial genomics company uBiome, were featured on AngelList early in their initial ... by launching an AngelList syndicate for individuals looking to make early stage investments ...
    Breaking Biology Technology:
    (Date:11/18/2015)... , November 18, 2015 ... published a new market report titled  Gesture Recognition Market ... Forecast, 2015 - 2021. According to the report, the global gesture ... is anticipated to reach US$29.1 bn by 2021, at ... North America dominated the global ...
    (Date:11/16/2015)... JOSE, Calif. , Nov 16, 2015 /PRNewswire/ ... developer of human interface solutions, today announced expansion ... Synaptics TouchView ™ touch controller and display ... architectural revolution of smartphones. These new TDDI products ... include TD4100 (HD resolution), TD4302 (WQHD resolution), and ...
    (Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
    Breaking Biology News(10 mins):